Tag: AstraZeneca

Five Russian startups present their projects at Cambridge Biomedical Campus

astrazeneca-cambridge
The winners of the Startup Challenge accelerator, organised jointly by the Skolkovo Foundation and AstraZeneca, are showcasing their inventions at the International Future Healthcare Forum.

AstraZeneca sells its rights for three corticosteroid drugs to Covis Pharma

astrazeneca
AstraZeneca has entered into an agreement with Covis Pharma B.V. (Switzerland) to sell its rights to the medicines Alvesco (ciclesonide), and Omnaris and Zetonna (ciclesonide).

Grünenthal signs $922 million deal with AstraZeneca

pharma-deal
Grünenthal announced that it has agreed to acquire AstraZeneca's European rights to Nexium and the global rights to Vimovo for a total consideration of up to $922 million (€ 811 million).

AstraZeneca signs new agreement with Innate Pharma

astrazeneca
AstraZeneca announced a new multi-term agreement with Innate Pharma, building on an existing collaboration, aimed at accelerating each company’s oncology portfolio.

AstraZeneca paid $110 million to settle lawsuits for misleading marketing

astrazeneca
Pharmaceutical giant AstraZeneca agreed to pay $110 million to the state of Texas to settle lawsuits alleging that the company falsely and misleadingly marketed two of its drugs.

AstraZeneca’s cancer drug gets positive CHMP opinion

astrazeneca
AstraZeneca and MedImmune announced that the CHMP of the European Medicines Agency has adopted a positive opinion, recommending a marketing authorisation of Imfinzi (durvalumab).

AstraZeneca sells European rights to its heart drug

astrazeneca
AstraZeneca has agreed to sell the commercial rights to Atacand and Atacand Plus in Europe to Cheplapharm Arzneimittel GmbH.

AstraZeneca and Geisinger join forces to create new asthma app

astrazeneca
AstraZeneca and Geisinger have partnered to improve asthma care by creating a suite of products that integrate into the electronic health record (EHR).

MedImmune and 4D Molecular Therapeutics to collaborate on AAV gene therapy

gene-therapy
MedImmune, the global biologics research and development arm of AstraZeneca, and 4D Molecular Therapeutics announced a collaboration to develop and commercialize a gene therapeutic for patients with chronic lung disease.

AstraZeneca and Skoltech signed a memorandum on HR development cooperation

skolkovo
AstraZeneca and Skolkovo Institute of Science and Technology announced the signing of a memorandum of intent for improving the professional competencies in the pharmaceutical industry.

AstraZeneca resumes sales of Nexium in Russia

astrazeneca-plant
AstraZeneca, a biopharmaceutical company, announced that it registered new maximum ex-work prices in Russia for the tablets of Nexium (esomeprazole) included in the List of Vital and Essential Drugs (VED List).

AstraZeneca cut prices for socially important drugs in Russia by 12-92%

fas russia
The maximum ex-works prices for 11 trade names (8 INNs) of vital and essential drugs have been reduced within a short period of time. This price reduction ranged from 12 to 92 percent.

Emulate and AstraZeneca will jointly develop Organs-on-Chips technology

organ-on-chips
Emulate Inc. has formed a collaborative partnership with AstraZeneca’s Innovative Medicines and Early Development (IMED) Biotech Unit to embed its Organs-on-Chips technology within the laboratories of the IMED.

AstraZeneca will develop novel stem cell-based therapies with SWIBCo

stem-cells
Procella Therapeutics and Smartwise entered the strategic research collaboration and commercialization agreement with AstraZeneca to develop novel stem cell-based therapies for heart failure and novel...

AstraZeneca will invest $90 million in India during the next five years

astrazeneca
Leading global science-led biopharmaceutical company AstraZeneca announced its decision of further investing $90 million over the next 5 years in India.

AstraZeneca and SKOLKOVO launched Startup Challenge 2018 acceleration program

skolkovo-astrazeneca
AstraZeneca and SKOLKOVO Foundation announced the launch of a joint acceleration program for projects in the area of oncology, cardiovascular, metabolic, kidney, respiratory, and autoimmune diseases.